

Date: June 04, 2026

To,

The Manager – Listing  
Dept of Corp. Services,  
BSE Limited  
P.J. Towers, Dalal Street, Fort,  
Mumbai – 400 001  
Scrip Code: 543593

The Manager – Listing  
National Stock Exchange of India Ltd.  
Exchange plaza, Bandra Kurla Complex  
Bandra East  
Mumbai – 400 051  
Symbol: DBOL

Dear Sir/Mam,

**Subject: Intimation of execution of Joint Venture Agreement with Orgonew Private Limited**

With reference to the captioned subject and in continuation to our outcome of Board Meeting dated April 20, 2026 and pursuant to the provisions of the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (herein after referred to as “Listing Regulations”), we wish to inform you that, the Company has signed a Joint Venture Agreement with Orgonew Private Limited today i.e. June 04, 2026 for development, manufacture, marketing, distribution, and commercialisation of phyto bio-active based functional food products and other products meant for human consumption and/or usage, through a Joint Venture Company (“JVC”).

The disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are furnished in **Annexure A**.

You are requested to take the above information on record.

Yours Sincerely,

**For Dhampur Bio Organics Limited**

**Ashu Rawat**  
**Company Secretary & Compliance Officer**

**Annexure A**

**Details of disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

S. N.	Particulars	Details
1.	Name of the parties with whom the agreement is entered into	First Party : Dhampur Bio Organics Limited Second Party : Orgonew Private Limited
2.	Purpose of entering into the agreement	To develop, manufacture, market, distribute, and commercialise phyto bio-active coated functional food products (such as curcumin-coated low-GI sugar) and other products meant for human consumption and/or usage, leveraging Orgonew’s proprietary nano-curcumin coating platform and allied process know-how together with DBO’s manufacturing infrastructure and commercial reach across General Trade, Modern Trade, E-Commerce, and Q-Commerce channels through a Joint Venture Company.
3.	Shareholding, if any, in the entity with whom the agreement is executed	The Company does not presently hold any shares in Orgonew Private Limited.  Pursuant to the Joint Venture Agreement, the Company will hold 74% and Orgonew will hold 26% of the equity share capital of the JVC.
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	<ul style="list-style-type: none"> <li>The Board will comprise of Three Directors including Chairman. Out of which 2 directors shall be appointed by Dhampur Bio Organics Limited and 1 director will be appointed by Orgonew Pvt Ltd.</li> <li>Shareholding of Orgonew in the JVC shall be maintained at 26% for the first three years from the date of closing.</li> </ul>

		<ul style="list-style-type: none"> <li>• Lock-in period : 5 years</li> </ul>
5.	Whether the said parties are related to promoter/ promoter group/ group companies in any manner. If yes, nature of relationship	<p>No.</p> <p>Orgonew Private Limited is not related to the promoter, promoter group, or any group company of the Company in any manner.</p>
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”	No
7.	In case of issuance of shares to the parties, details of issuance	Pursuant to the Joint Venture Agreement, the Company will hold 74% and Orgonew will hold 26% of the equity share capital of the JVC.
8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	As mentioned in point no. 4.